Mayo Clinic lab services pact filed by Aspira (OTC: AWHL)
Rhea-AI Filing Summary
Aspira Women’s Health Inc. filed an amended report to provide the full Laboratory Services Agreement it entered into with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories. The agreement is effective as of December 16, 2025 and had previously been disclosed as a material definitive agreement.
The amendment mainly adds the agreement as Exhibit 10.1 after completing redactions of private or confidential information. No financial results or other business updates are included beyond this contract filing.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Aspira Women’s Health (AWHL) report in this amended 8-K?
Aspira Women’s Health filed an amended report to add the Laboratory Services Agreement with Mayo Clinic Laboratories as Exhibit 10.1. The agreement was previously disclosed but not filed until redactions of private or confidential information were completed.
Who is Aspira Women’s Health’s partner in the new Laboratory Services Agreement?
Aspira’s Laboratory Services Agreement is with Mayo Collaborative Services, Inc., doing business as Mayo Clinic Laboratories. The amendment formally files this agreement as an exhibit, reflecting its status as a material definitive agreement between the two organizations.
When did the Aspira–Mayo Clinic Laboratories agreement become effective?
The Laboratory Services Agreement between Aspira Women’s Health and Mayo Clinic Laboratories is effective as of December 16, 2025. The amended report filed later simply adds the finalized, partially redacted contract as Exhibit 10.1 for public reference.
Why did Aspira Women’s Health file an amendment to its Form 8-K?
Aspira filed the amendment because the Laboratory Services Agreement with Mayo Clinic Laboratories was not attached initially. The company needed additional time to finalize appropriate redactions of private or confidential information before including the contract as Exhibit 10.1.
Does this Aspira (AWHL) filing include new financial results or earnings data?
No, the filing focuses solely on attaching the Laboratory Services Agreement with Mayo Clinic Laboratories as a material definitive agreement. It does not provide revenue, earnings, or other financial performance data, and only updates the exhibit section of the prior report.
What exhibits are included in this Aspira Women’s Health amended report?
The amended report lists Exhibit 10.1, the Laboratory Services Agreement dated December 16, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document. These exhibits complete the earlier disclosure of the agreement.